According to latest GlobalData survey, 59% of healthcare pharma professionals have a negative sentiment about Brexit’s impact on the UK healthcare sector.
Negative sentiment amongst the healthcare pharma professionals regarding the impact of Brexit on the UK healthcare sector has increased over the last 3 months, according to GlobalData, a leading data and analytics company.
More pharma professionals against Brexit
The report reveals that 59% of healthcare industry professionals now have a negative sentiment about the impact of Brexit on the UK healthcare sector, compared to only 42% of pharma professionals who expressed the same opinion in June 2018.
Healthcare professionals from the US, UK and EU took part in the survey with respondents from the EU expressing the biggest fall in Brexit confidence, the report showed a 28% increase in negative sentiment since the previous survey.
This research is based on a quarterly survey of participants from the pharmaceutical industry, both within and outside the UK, who were asked about the impact of Brexit on the healthcare sector as well as their evolving sentiment towards Brexit.
Moreover, 83% of UK pharma professionals also say the UK will not be an attractive destination for healthcare research.
The UK healthcare sector and Brexit
Alexandra Annis, MS, Managing Healthcare Analyst at GlobalData, commented on the survey: “One potential explanation for the increase in negative sentiment in Q3 is less clarity over the future of Brexit, especially in the EU. The Brexit process has a long way to go and is filled with uncertainty as a ‘no deal’ Brexit becomes an increasing possibility.’’
The UK pharmaceutical industry is one of the country’s largest and perhaps the most dynamic sectors, and a major contributor to the economy. As well as being the home to pharmaceutical giants such as GlaxoSmithKline and AstraZeneca, many other leading international pharmaceutical companies have sizeable operations in the UK.
Annis continues: ‘‘Given the importance of the pharmaceutical industry to the UK economy, the current negativity around Brexit must be of concern. Understanding the impact of Brexit on research and manufacturing, corporate strategy, and relocation as well as tracking the evolving sentiment of Brexit’s impact on the UK healthcare industry is of significant importance to help pharmaceutical companies make the most of Britain leaving the EU.”
